Table 3. Logistic regression analysis of ORR in NSCLC patients treated with camrelizumab.
Variables | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | ||
Camrelizumab treatment line | |||||
First line | Ref | ||||
Second line | 0.278 (0.133–0.583) | 0.001 | 0.347 (0.162–0.741) | 0.006 | |
≥ Third line | 0.121 (0.042–0.35) | <0.001 | 0.126 (0.043–0.367) | <0.001 | |
Age | |||||
<70 years | Ref | ||||
≥70 years | 0.941 (0.529–1.674) | 0.837 | |||
Sex | |||||
Male | Ref | ||||
Female | 0.649 (0.382–1.103) | 0.11 | |||
Histology | |||||
Adenocarcinoma | Ref | ||||
Squamous cell carcinoma | 1.543 (0.982–2.425) | 0.06 | |||
Other/unspecified | 2.739 (0.747–10.038) | 0.128 | |||
Smoking status | |||||
Never | Ref | ||||
Current/former | 1.154 (0.726–1.834) | 0.544 | |||
Brain metastasis | |||||
No | Ref | ||||
Yes | 0.761 (0.404–1.434) | 0.398 | |||
Liver metastasis | |||||
No | Ref | ||||
Yes | 0.284 (0.105–0.763) | 0.013 | 0.324 (0.115–0.915) | 0.033 | |
Baseline antibiotics | |||||
No | Ref | ||||
Yes | 1.559 (0.766–3.174) | 0.221 | |||
Baseline steroids | |||||
No | Ref | ||||
Yes | 0.749 (0.461–1.218) | 0.244 | |||
Tumor stage | |||||
IB–IIIA | Ref | ||||
IIIB–IV | 0.483 (0.253–0.922) | 0.027 | |||
Duration of camrelizumab use | |||||
<6 cycles | Ref | ||||
≥6 cycles | 1.974 (1.264–3.084) | 0.003 | 1.843 (1.149–2.956) | 0.011 | |
Patterns of camrelizumab use | |||||
Monotherapy | Ref | ||||
Plus CT | 2.114 (0.895–4.995) | 0.088 | |||
Plus anti-angiogenesis | 0.955 (0.303–3.009) | 0.937 | |||
Plus CT + anti-angiogenesis | 1.633 (0.637–4.186) | 0.307 |
ORR, objective response rate; NSCLC, non-small cell lung cancer; OR, odds ratio; CI, confidence interval; CT, chemotherapy.